Plans to expand diabetes care and structural heart segments drive strong growth.
Abbott announced it expects to launch its first pulsed field ablation (PFA) device outside the U.S. in 2025, with CE Mark approval anticipated in the first half of the year and FDA approval in 2026. CEO Robert Ford highlighted the Volt PFA system, which combines a balloon-in-basket catheter with a heart mapping solution, as a key growth driver in its electrophysiology segment.
Electrophysiology Segment Growth
- 2024 Sales: $2.47 billion (+12.3% YoY).
- 2025 Outlook: High single-digit growth, with potential acceleration in the second half as Volt launches.
PFA offers a minimally invasive alternative for treating heart arrhythmias, with faster procedures and fewer complications compared to heat- or cold-based methods. While competitors like Medtronic, Boston Scientific, and J&J have introduced similar devices, Abbott aims to establish a strong position with Volt and related mapping technologies.
Diabetes Care and Structural Heart Leading Growt
- Diabetes Care:
- 2024 Sales: $6.81 billion (+18.1% YoY), driven by continuous glucose monitors (CGMs).
- Focus areas include expanding CGM use among intensive insulin users, basal insulin users, and over-the-counter glucose sensors.
- Structural Heart:
Abbott plans to capitalise on increased global demand for innovative heart devices.
Outlook for 2025
Abbott expects robust performance across electrophysiology, diabetes care, and structural heart segments, solidifying its leadership in innovative healthcare solutions.
Follow MEDWIRE.AI for updates on Abbott’s innovations and global medical technology trends!
